Dosimetric and biological comparisons of single planning and double plannings for bilateral lung cancer SBRT planning based on the Cyber-Knife system

Objective The aim is to investigate the influence of single planning (Plan S) and double plannings (Plan D) on bilateral lung cancer stereotactic body radiation therapy planning from the perspective of dosimetry and biology respectively. Methods Cases with bilateral lung cancer patients who had undergone SBRT with the Cyber-Knife were enrolled, and a single planning and double plannings were designed in the Multiplan@4.2 treatment planning system equipped with the Cyber-Knife system. The single plan was to optimize the two target volumes in a separate plan, while the dual plan is to optimize two target volumes respectively in two separate plans, then perform dose superposition. Then based on the dosimetric results, the biological parameters were calculated. Thus the quality of SBRT plans for those bilateral lung cancer designed by the two methods were compared and evaluated according to the dosimetric and biological results. Results The dose distribution of both planning target volumes and surrounding organs at risk in Plan S and Plan D could meet the clinical prescription requirements. The target conformity index and the new conformity index of PTV were closer to 1 in the Double plannings, and the dose gradient GI in the Plan D was smaller than Plan S. For organs at risks, the doses received by the Plan D were relatively small. In terms of biological models, for the equivalent uniform dose of normal lung tissue, heart and esophagus, the Plan D was 6.51% (P=0.045), 19.8% (P=0.022), 27.08% (P>0.05) lower than Plan S respectively. The results showed that the equivalent uniform dose of normal tissue in the Plan D was lower relative to Plan S. Conclusions Dosimetric and biological results show that both the use of Plan D have an advantage of protecting normal tissues, and it was suggested that to design double plannings for bilateral lung cancer stereotactic body radiation therapy planning based on Cyber-Knife in the clinical practice.

[1]  Wanqing Chen,et al.  Cancer statistics in China and United States, 2022: profiles, trends, and determinants , 2022, Chinese medical journal.

[2]  H. Yue,et al.  Potential Defects and Improvements of Equivalent Uniform Dose Prediction Model Based on the Analysis of Radiation-Induced Brain Injury , 2022, Frontiers in Oncology.

[3]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[4]  Xianzhi Zhao,et al.  Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer , 2018, Radiation oncology.

[5]  S. Senan,et al.  Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors: New insights and approaches. , 2018, Lung cancer.

[6]  A. Louie,et al.  Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk? , 2018, Radiation Oncology.

[7]  H. Onishi,et al.  Stereotactic body radiotherapy for early stage lung cancer-historical developments and future strategies. , 2017, Chinese clinical oncology.

[8]  Shingo Miyamoto,et al.  Efficacy and safety of stereotactic body radiotherapy using CyberKnife in Stage I primary lung tumor , 2017, Japanese journal of clinical oncology.

[9]  P. Blumenfeld,et al.  Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥80years old): Extremely safe and effective. , 2017, Journal of geriatric oncology.

[10]  Jungwon Kwak,et al.  Verification of Accuracy of CyberKnife Tumor-tracking Radiation Therapy Using Patient-specific Lung Phantoms. , 2015, International journal of radiation oncology, biology, physics.

[11]  C. Belka,et al.  Analysis of equivalent uniform dose (EUD) and conventional radiation treatment parameters after primary and re-irradiation of malignant glioma , 2013, Radiation oncology.

[12]  Y. Korogi,et al.  Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. , 2013, Lung cancer.

[13]  Jean-François Carrier,et al.  Predictive parameters of CyberKnife fiducial-less (XSight Lung) applicability for treatment of early non-small cell lung cancer: a single-center experience. , 2013, International journal of radiation oncology, biology, physics.

[14]  O. Sauer,et al.  Definition of stereotactic body radiotherapy , 2013, Strahlentherapie und Onkologie.

[15]  S. Dieterich,et al.  The CyberKnife in clinical use: current roles, future expectations. , 2011, Frontiers of radiation therapy and oncology.

[16]  M. Schell,et al.  Stereotactic body radiation therapy: the report of AAPM Task Group 101. , 2010, Medical physics.

[17]  E. Wilcox,et al.  Comparison of planned dose distributions calculated by Monte Carlo and Ray-Trace algorithms for the treatment of lung tumors with cyberknife: a preliminary study in 33 patients. , 2010, International journal of radiation oncology, biology, physics.

[18]  Dwight E Heron,et al.  Synchrony--cyberknife respiratory compensation technology. , 2008, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[19]  Steve Webb,et al.  Dosimetric investigation of lung tumor motion compensation with a robotic respiratory tracking system: an experimental study. , 2008, Medical physics.

[20]  B. Lippitz,et al.  A simple dose gradient measurement tool to complement the conformity index. , 2006, Journal of neurosurgery.

[21]  R. Mcgarry,et al.  Stereotactic body radiotherapy for bilateral primary lung cancers: the Indiana University experience. , 2006, International journal of radiation oncology, biology, physics.

[22]  R. Mohan,et al.  Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas. I: dosimetric results. , 2003, International Journal of Radiation Oncology, Biology, Physics.

[23]  A. Jilaihawi,et al.  The management of second primary lung cancers. A single centre experience in 15 years. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[24]  H. Chin,et al.  Palliative Radiotherapy for Synchronous Bilateral Lung Cancers , 2001, American journal of clinical oncology.

[25]  S. Adebonojo,et al.  The results of modern surgical therapy for multiple primary lung cancers. , 1997, Chest.

[26]  M. Moerland,et al.  A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate. , 1997, International journal of radiation oncology, biology, physics.

[27]  L Souhami,et al.  Radiation Therapy Oncology Group: radiosurgery quality assurance guidelines. , 1993, International journal of radiation oncology, biology, physics.

[28]  S. Loo,et al.  Synchronous bilateral squamous cell carcinoma of the lung successfully treated using intensity-modulated radiotherapy. , 2012, The British journal of radiology.

[29]  A. Niemierko Reporting and analyzing dose distributions: a concept of equivalent uniform dose. , 1997, Medical physics.

[30]  H. Laborit,et al.  [Experimental study]. , 1958, Bulletin mensuel - Societe de medecine militaire francaise.